146 related articles for article (PubMed ID: 23140823)
1. Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons.
Catalá-López F
Eur J Cancer; 2013 Mar; 49(4):984-5. PubMed ID: 23140823
[No Abstract] [Full Text] [Related]
2. The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb S; Shamash J; Stockdale A; Lim L; Nathan P; Chowdury S
Eur J Cancer; 2013 Mar; 49(4):986-7. PubMed ID: 23138000
[No Abstract] [Full Text] [Related]
3. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
4. PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.
Sun M; Larcher A; Schiffmann J; Karakiewicz PI
J Clin Oncol; 2014 Nov; 32(33):3783. PubMed ID: 25267763
[No Abstract] [Full Text] [Related]
5. PISCES trial: the end does not always justify the means.
Barni S; Petrelli F
J Clin Oncol; 2014 Nov; 32(33):3782-3. PubMed ID: 25267749
[No Abstract] [Full Text] [Related]
6. Reply to S. Barni et Al and M. Sun et Al.
Garnick MB
J Clin Oncol; 2014 Nov; 32(33):3785. PubMed ID: 25267752
[No Abstract] [Full Text] [Related]
7. Reply to S. Barni et Al and M. Sun et Al.
Escudier B; Porta C; Powles T; Eisen T; Sternberg CN; Mehmud F; Cella D
J Clin Oncol; 2014 Nov; 32(33):3783-4. PubMed ID: 25267750
[No Abstract] [Full Text] [Related]
8. How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?
Garnick MB
J Clin Oncol; 2014 May; 32(14):1392-3. PubMed ID: 24687838
[No Abstract] [Full Text] [Related]
9. Kidney cancer: in crossover study, patients and physicians prefer pazopanib.
Phillips R
Nat Rev Urol; 2014 May; 11(5):246. PubMed ID: 24731995
[No Abstract] [Full Text] [Related]
10. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
11. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
13. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Escudier B; Porta C; Bono P; Powles T; Eisen T; Sternberg CN; Gschwend JE; De Giorgi U; Parikh O; Hawkins R; Sevin E; Négrier S; Khan S; Diaz J; Redhu S; Mehmud F; Cella D
J Clin Oncol; 2014 May; 32(14):1412-8. PubMed ID: 24687826
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
16. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
[TBL] [Abstract][Full Text] [Related]
17. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma on Sunitinib.
Ahmad M; Prasad S; Krishna MV; Lavingia V
Indian J Cancer; 2016; 53(1):112-3. PubMed ID: 27146756
[No Abstract] [Full Text] [Related]
19. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
20. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].
Trump D
Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
